For research use only. We do not sell to patients.
Ionizable lipids / CICL-1 (L829)
CICL-1 (L829) chemical structure
Product imageResearch use only
CAT. NO. DC99010Featured

CICL-1 (L829)

Pack size & price

USD
TotalUS$600
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

CICL-1 (catalog alias L829) is an ionizable lipid for targeted RNA-delivery research. The cited L829 study reports in vivo CAR expression, B-cell depletion and leukemia-model activity using antibody-targeted LNPs, with a serious adverse event in a repeat-dose primate study. The catalog lipid is supplied for research; the reported outcomes depend on the complete LNP, targeting ligand and RNA cargo.

Open full Formulation & Performance →

Literature evidence · DC99010

Formulation & Performance

Mouse and nonhuman-primate evidence for L829, with targeting, efficacy and tolerability kept separate.

The catalog mapping to L829 is retained from the existing approved record. The Science main article does not independently establish the commercial structure or the Compound A-11 alias.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
L829 / CICL-1DC990101013.4Not assignedNot calculable from disclosed data
Targeting ligand-lipid conjugateNot uniquely mappedNot establishedNot assignedNot calculable from disclosed data
Other three lipid componentsNot uniquely mappedNot establishedNot assignedNot calculable from disclosed data

The molecular weight shown for CICL-1 is a catalog value. Complete five-lipid identity, proportions and N/P await Supplementary Table S1; no patent formulation is substituted.

Component mass calculator

Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
L829 / CICL-1——
Targeting ligand-lipid conjugate——
Other three lipid components——

Study identity and formulation boundary

ItemEvidence
Source compoundL829 in Hunter et al., Science (2025). CICL-1 / Compound A-11 is the catalog mapping; those names and a chemical structure are not disclosed in the reviewed main paper.
TargetingUntargeted LNP, CD5-targeted LNP and CD8-targeted LNP are separate systems. Targeting ligand and cargo influence performance.
CompositionFive-lipid formulation is referenced to Supplementary Table S1. Exact component identities, molar ratios and N/P remain unverified without that table.
Particle propertiesSize, PDI, encapsulation and apparent pKa are not assigned from unrelated patents.

Hunter et al., main article and references to supplementary methods; existing reviewed main-article record retained. New SI retrieval was blocked on 28 October 2026.

Mouse delivery and leukemia experiments

ExperimentReported outcomeContext / source
Untargeted reporter LNPLess liver and spleen luciferase expression than the ALC-0315 benchmark.Wild-type C57BL/6 mice; main Fig. 1B. Reporter expression is distinct from particle accumulation.
Lipid persistenceL829 cleared more rapidly from mouse liver; ALC-0315 remained elevated for at least 7 days.Main Fig. 1C; compound clearance endpoint, not RNA expression duration.
Humanized leukemia modelNear-complete tumor clearance in 4/5 mice two days after the first dose; 5/5 three days after the second dose.CD8-targeted anti-CD19 CAR mRNA; PBMC/Nalm6 xenograft, 30 micrograms IV, twice weekly for five doses; Fig. 3G.

Nonhuman-primate CAR expression and B-cell depletion

EndpointReported resultStudy context
Peripheral B cellsDecline by 6 hours and near-undetectable levels by 24 hours after the first dose.CD8-targeted anti-CD20 CAR mRNA; 22 cynomolgus monkeys across three studies, 0.1-2.0 mg/kg, three IV doses 72 hours apart; Fig. 4.
CD8 T-cell CAR expressionUp to 85% after the third dose.Upper observed value, not mean or guarantee; minimal CD4 T-cell CAR expression reported.
CD8 NK-cell CAR expressionUp to 95% after the third dose.Dose-dependent response; Fig. 4C.
B-cell recoveryRepopulation started around day 21 and approached baseline by day 35.1-1.5 mg/kg follow-up; Fig. 5. Predominantly naive repopulation was interpreted by the authors as suggestive of immune reset.

Tolerability: retain the adverse result

StudyFindingInterpretation
Rat CD5-targeted L829Reported tolerated up to 5 mg/kg without adverse observations.Main Fig. 1D; does not establish the safety of every cargo/targeting combination.
Single-dose cynomolgus studyA 3 mg/kg IV dose was reported as tolerated.Main Fig. 1E; separate from repeat CAR dosing.
Repeat anti-CD20 CAR dosingOne monkey in the 1.5 mg/kg group developed a serious immune-effector-cell-associated event 72 hours after dose 3 and was euthanized.Main text p. 1316. This event must be considered alongside depletion efficacy; no blanket nontoxic claim.

Original study figures

Mouse and primate results: Figures 1 and 3-5 — Original source figures.

References and source locations

  1. Hunter TL et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311-1317 (2025). DOI: 10.1126/science.ads8473.
CAS No.Not available
Chemical NameCICL-1 (L829)
Synonyms​​L-829, ​​L 829, Capstan-lipid-CICL-1, Capstanlipid CICL1, CICL1, CICL 1, CICL-1, Lipid 829, L-829, L 829, Compound A-11, DC60860
SMILESCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCC)CC(=O)OCCN(CCOC(=O)CC(COC(=O)CCCCCCCC)COC(=O)CCCCCCCC)C(=O)OCCN(C)C
FormulaC55H100O14N2
M.Wt1013.40
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
Publication
  1. Hunter TL et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311-1317 (2025). DOI: 10.1126/science.ads8473.
Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg9.8678 mL1.9736 mL986.78 μL
25 mg24.6694 mL4.9339 mL2.4669 mL
50 mg49.3389 mL9.8678 mL4.9339 mL
100 mg98.6777 mL19.7355 mL9.8678 mL
250 mg246.6943 mL49.3389 mL24.6694 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.